MIM
BIOA

MetLife Investment Management’s BioAge Labs BIOA Stock Holding History

MetLife Investment Management’s Portfolio BIOA Stock Details BIOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$293K Buy
16,725
+2,288
+16% +$44.1K ﹤0.01% 2016
2025
Q4 		$191K Buy
+14,437
New +$128K ﹤0.01% 2296

Other funds holding BIOA

ACM
AH Capital Management Menlo Park, California $1.29B AUM 26.81% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

MetLife Investment Management's BIOA Position: Q1 2026 in Review

MetLife Investment Management increased its BioAge Labs (BIOA) stake by 16% in Q1 2026, buying an estimated $44.1K and bringing the position to 16,725 shares worth $293K. The position accounts for ﹤0.01% of the portfolio, ranked #2016.

MetLife Investment Management first reported a position in BIOA in Q4 2025 and has held it in 2 quarters since. 144 funds tracked by Wall St. Rank hold BIOA as of Q1 2026.

  • MetLife Investment Management held 16,725 shares of BioAge Labs worth $293K as of Q1 2026.
  • MetLife Investment Management bought 2,288 BioAge Labs shares in Q1 2026, an estimated $44.1K.
  • BioAge Labs made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2016 holding.
  • MetLife Investment Management first reported a position in BioAge Labs in Q4 2025 and has held it in 2 quarters since.
  • 144 funds tracked by Wall St. Rank held BioAge Labs as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.